Bod Australia is launching a new cannabigerol (CBG) product under its MediCabilis brand in the UK through select doctors and healthcare physicians.
Preliminary research indicates that the non-intoxicating cannabinoid compound has unique pharmacological actions and the potential to address alternative therapeutic areas to THC and CBD.
Bod said it expects the introduction of MediCabilis CBG 50 to support incremental market growth across the region, as well as providing additional R&D and clinical research opportunities.
The company also reported strong quarter-on-quarter MediCabilis prescription growth in the UK, filling 59 units in Q3 FY21, a 90% increase on Q2’s total of 31.
It expects prescription volumes to continue to grow following the launch of the new CBG product, the scale up of medicinal cannabis patient study Project Twenty21 and ongoing educational initiatives promoting the company’s range with approved UK prescribers.
CEO Jo Patterson said: “CBG has been reported to be the ‘next CBD’ and has a growing market demand. Published scientific literature suggests CBG has potential anti-inflammatory benefits, so the launch of MediCabilis CBG 50 in oil form will provide Bod with an important first-mover advantage in what will become a significant market.”